KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVS) Shares Outstanding (Diluted Average) (2016 - 2026)

Novartis Ag's Shares Outstanding (Diluted Average) history spans 16 years, with the latest figure at $1.6 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Diluted Average) fell 9.34% to $1.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.6 million, a 9.34% decrease, with the full-year FY2025 number at $7.2 million, up 21.81% from a year prior.
  • Shares Outstanding (Diluted Average) hit $1.6 million in Q1 2026 for Novartis Ag, down from $7.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for NVS hit a ceiling of $7.2 million in Q4 2025 and a floor of $990000.0 in Q1 2022.
  • Historically, Shares Outstanding (Diluted Average) has averaged $3.0 million across 5 years, with a median of $2.8 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): tumbled 74.13% in 2022 and later skyrocketed 165.14% in 2024.
  • Tracing NVS's Shares Outstanding (Diluted Average) over 5 years: stood at $2.8 million in 2022, then skyrocketed by 49.09% to $4.1 million in 2023, then soared by 43.17% to $5.9 million in 2024, then increased by 21.81% to $7.2 million in 2025, then plummeted by 76.92% to $1.6 million in 2026.
  • Business Quant data shows Shares Outstanding (Diluted Average) for NVS at $1.6 million in Q1 2026, $7.2 million in Q4 2025, and $5.9 million in Q3 2025.